Innovation is of no worth if it doesn’t provide better outcomes for patients. Indeed, such advancements should hold as centre the amelioration of the overall patient experience.
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme.
Rates of cancer among people aged 24 and below are rising fast, but health systems are often not catering well enough to the specific needs of this age group.
Digital technologies are transforming the pharmaceutical industry's ability to meet the evolving needs of healthcare professionals (HCPs) and patients.
Ensuring equitable access to medicines is a cornerstone of the commitments many pharmaceutical companies make to their customers, patients, and stakeholders – but, recently, there has been